Chloral hydrate
100mg/mL oral mixture

Note:
Practice poi
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

This is a High Risk Medication
Potentially toxic medication. An overdose can be rapidly fatal.

Dose and Indications

Sedation

Oral
8mg/kg/dose every 6 to 8 hours

Procedural sedation

Oral
25 to 75 mg/kg as a single dose, given 30 minutes before the procedure

Preparation and Administration

Oral
For oral use, the mixture should be diluted or administered after feeding to reduce gastric irritation

There are TWO STEPS to the dilution process.

| STEP ONE: Draw up the dose of chloral hydrate using the 100mg/mL oral mixture |
| STEP TWO: Dilute with an equal volume of water for injection or enteral feed.
For preterm babies it is preferred to use water for injection as the choice of diluent. |
Adverse Effects

Common
Gastric irritation, vomiting and diarrhoea (particularly if given on an empty stomach), paradoxical excitement
Respiratory depression, cardiac depression with high or repeated dosing

Rare
Vasodilation, hypotension, arrhythmias, hyperbilirubinaemia

Monitoring
> Respiration
> Heart rate and oxygen saturation
> Blood pressure
> Liver function tests (if patient receiving regular dosing)
If used for procedural sedation monitor for at least 4 hours. Preterm infants have an increased risk of bradycardia for up to 24 hours post administration

Practice Points
> Chloral hydrate is of no use in the control of pain
> Onset of action is approximately 15 minutes with duration of action up to 2 hours
> Should be used with caution in patients with renal or hepatic disease due to the potential for accumulation
> Repeated administration can lead to accumulation
> May increase the elimination of phenytoin thereby reducing its therapeutic action
> Chloral hydrate is hyperosmolar. Use caution in in preterm infants at increased risk of necrotising enterocolitis
> Half-life of active metabolite of chloral hydrate may be prolonged in preterm infants, increasing the risk of prolonged recovery time and oxygen requirement
Chloral hydrate
100mg/mL oral mixture

Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: Health.NeoMed@sa.gov.au
Endorsed by: Commissioning and Performance, SA Health
Next review due: 7/12/2026
ISBN number: 978-1-76083-386-2
CGQS reference: NMG009
Policy history:

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/12/2021</td>
<td>V2.0</td>
<td>Domain Custodian, Clinical Governance, Safety and Quality</td>
<td></td>
</tr>
<tr>
<td>9/3/2018</td>
<td>V1.1</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>New Template</td>
</tr>
<tr>
<td>15/05/2015</td>
<td>V1.0</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Original SA Health Safety and Quality Strategic Governance Committee approved version</td>
</tr>
</tbody>
</table>